ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS
Endonovo Therapeutics, Inc. (OTCQB: ENDV) plans to explore strategic alternatives to maximize shareholder value for its SofPulse® PEMF assets. This initiative may involve discussions with investment bankers, equity fund managers, and medical technology consultants. CEO Alan Collier expressed confidence in expanding distribution channels and commercializing SofPulse®, which has shown positive clinical effects on various inflammatory diseases. The company aims to partner with global medical device participants for growth, focusing on joint ventures and licensing agreements.
- Exploring strategic alternatives could enhance shareholder value.
- CEO expresses confidence in the potential of SofPulse® technology.
- The company has a strong patent portfolio related to various inflammatory diseases.
- SofPulse® assets are FDA cleared for postoperative pain and edema reduction.
- None.
Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets.
This may include, but is not limited to, discussions with investment bankers, equity fund managers, global medical technology consultants and other investment groups.
“Endonovo’s management has created momentum for investment and expansion amongst larger, better-known participants in the medical device/technology markets to optimize significant expansion of distribution channels,” according to CEO Alan Collier. “We are extremely confident that our revolutionary medical technology can achieve extensive global reach with an aggressive expansion through strategic relationships,” he said.
Collier continued: “We are increasingly confident that our expanded business strategy for SofPulse® can enable us to achieve our long-term goals for growth and profitability. However, to create an effective commercialization plan, a more expanded and aggressive strategy is needed. Therefore, we are looking to partner with global participants in the medical device market to spur the expansion. We expect such investment alternatives to include partnerships, joint ventures, distribution and licensing agreements for our breakthrough PEMF medical technology.
Endonovo’s current patent portfolio for PEMF Electroceutical® Therapy has demonstrated strong clinically meaningful bioeffects relevant to multiple diseases or disorders with an inflammatory component, including ischemic stroke, multiple sclerosis, traumatic brain injury, cardiovascular disease and peripheral vascular disease. In addition, the SofPulse® assets are FDA cleared for reduction of pain and edema postoperatively.
Collier concluded: “I want to emphasize to shareholders that we have great faith in our IP and branding of SofPulse® in the marketplace for the long term. We look to vastly accelerate the short-term benefits to all stakeholders in the Company by aggressively seeking strategic alternatives utilizing the valuable assistance of an investment banking, medical device consultants, distributors and/or mergers and acquisitions specialist firms.”
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is now structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives with many of its products marketed under the SofPulse® brand name; and its Build Up Strategy – acquiring high margin specialty service providers in the construction industry.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Steve Barnes
(800) 701-1223 Ext. 108
sbarnes@endonovo.com
www.endonovo.com
Media Contact:
Gregory A. McAndrews
Greg McAndrews & Associates
(310) 804-7037
greg@gregmcandrews.com
